

# Joseph Cuthbert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9259136/publications.pdf>

Version: 2024-02-01

24  
papers

586  
citations

840776

11  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 43-52.	1.0	2
2	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <sc>HOMAGE</sc> clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 321-331.	7.1	16
3	Criteria for Iron Deficiency in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 341-351.	2.8	73
4	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <sc>HOMAGE</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 771-778.	7.1	7
5	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1559-1568.	7.1	12
6	Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2021, 139, 57-63.	1.6	4
7	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	4
8	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021, 9, 268-277.	4.1	46
9	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 163.	6.8	7
10	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMICS™ in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021, 42, 684-696.	2.2	77
11	The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1831-1840.	7.1	14
12	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	3
13	High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. <i>Cardiovascular Research</i> , 2020, 116, 91-100.	3.8	58
14	Hypochloraemia in Patients with Heart Failure: Causes and Consequences. <i>Cardiology and Therapy</i> , 2020, 9, 333-347.	2.6	22
15	<p>Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 715-726.	2.0	10
16	The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. <i>Clinical Research in Cardiology</i> , 2019, 108, 185-193.	3.3	15
17	Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 904-916.	7.1	100
18	91...The relation between thyroid dysfunction and mortality in patients with chronic heart failure. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Are there patients missing from community heart failure registers? An audit of clinical practice. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 291-298.	1.8	8
20	Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. <i>European Journal of Heart Failure</i> , 2018, 20, 1426-1435.	7.1	56
21	New pharmacological approaches in heart failure therapy: developments and possibilities. <i>Future Cardiology</i> , 2017, 13, 173-188.	1.2	0
22	Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?. <i>Current Heart Failure Reports</i> , 2017, 14, 147-157.	3.3	9
23	Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. <i>Medical Devices: Evidence and Research</i> , 2017, Volume 10, 123-132.	0.8	2
24	Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. <i>Heart</i> , 2015, 101, 1149-1158.	2.9	41